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Whilst the inhaled route is the first line administration method in the management of asthma,
it is well documented that patients can have problems adopting the correct inhaler technique
and thus receiving adequate medication. This applies equally to metered dose inhalers and dry
powder inhalers and leads to poor disease control and increased healthcare costs. Reviews
have highlighted these problems and the recent European Consensus Statement developed
a call to action to seek solutions.
This review takes forward the challenge of inhaler competence by highlighting the issues and
suggesting potential solutions to these problems. The opportunity for technological innovation
and educational interventions to reduce errors is highlighted, as well as the specific challenges
faced by children. This review is intended as a policy document, as most issues faced by
patients have not changed for half a century, and this situation should not be allowed to
continue any longer. Future direction with respect to research, policy needs and practice,
together with education requirements in inhaler technique are described.
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Inhalers are the most common type of medication devices
used in asthma treatment. However, they are often used
sub-optimally leading to uncontrolled asthma and increased
costs, either as a result of uncontrolled disease, or
increased drug utilization for relief medication or preven-
tative therapy.1 This remains a common problem in asthma
and COPD.2,3
The recent ADMIT (Aerosol Drug Management Improve-
ment Team) series discussed current knowledge of asthma
management, its components, factors that may limit
patients’ ability to achieve optimal asthma outcomes and
instruments to measure asthma control, and attempted to
raise awareness that correct device use is crucial for
successful treatment.4e9 A call for action to the medical
community recently published in the European Respiratory
Journal laid out how this might be practically imple-
mented.10 The present paper goes further by considering all
aspects of the misuse of inhalers and aims to provide an
overview of the problem and recommend solutions.
The worldwide costs associated with the management of
asthma in adults and children are substantial, from both
the healthcare payer and the societal perspective. In the
US, the total direct annual cost of asthma has been esti-
mated to be as much as $1.48 billion.11,12 In Europe, the
estimated average cost for a child with asthma ranged from
V88312 to V220213 per year; for adults these costs ranged
from V63213 to V2745.14
Pharmaceutical expenditure represents an increasing
share of total direct medical costs. A UK review estimated
the annual cost of asthma to be £752.6 million, of which 8%
was due to hospital admissions, 13% to general practice
consultations and 79% to community prescriptions.15 Indi-
rect costs represent 40e50% of the total societal burden of
asthma.
Research findings show that costs increase significantly
with increasing asthma severity.16 In the US TENOR study,
healthcare expenditure for an uncontrolled patient is more
than double that of a controlled patient.12
Improper inhalation technique can lead to decreased
efficacy through reduced deposition of medication in the
lungs. Critical inhaler handling errors, likely to significantly
impair delivery of adequate medication, that are associ-
ated with different inhaler devices are listed in Table 1. In
a review of 21 studies looking at misuse of metered dose
inhalers, poor technique was estimated to be prevalent in
14e90% (with an average of 50%) of cases.17 It is perhaps
not surprising that patients often use their device incor-
rectly since healthcare professionals’ understanding of the
correct use of these devices is also poor. In a study of
medical interns, only 5% were found to be able to correctly
use an MDI device.18 The same study showed that
a substantial increase in correct use occurred after a one-
on-one training session.18 In a systematic review of
educational programs for self-management of asthma in
children and adolescents, education was associated with
improved lung function, reduced school absenteeism,
decreased numbers of days with restricted activities and
fewer visits to emergency departments.19 Switching
patients from inhalers to other inhalers requiring technicaltraining can reduce control, if not accompanied by a GP
consultation, due to increased levels of misuse caused by
confusion over appropriate inhaler technique for different
devices.20 In an observational study of prospectively
recruited consecutive patients, asthma instability was
associated with inhaler misuse.17 In one of the few studies
in this area, patients randomized to a short, pharmacy-led,
training program in the use of their inhaler achieved
significantly improved clinical and quality of life outcomes
compared to a control group who received no training.21
The potential economic advantages of improving inha-
lation technique are likely to be compelling. Poor inhaler
technique leads either to worse asthma control than could
otherwise be achieved, or to stepping up to higher doses or
prescribing of additional therapies such as fixed dose
combinations in patients who could manage well with
inhaled steroid therapy alone. Hence there is tremendous
potential for improved inhaler technique to lead to better
asthma control and reduced prescription costs. While it is
important to consider the costs of interventions to improve
inhaler technique, given the financial and health burden of
poor asthma control, it is likely that a program which
effectively shows the impact of improved inhaler technique
on asthma management would be considered cost effective
and should be cost saving. Real-life research either in terms
of pragmatic trials or observational research are needed to
confirm the true economic advantages of improving inha-
lation technique. In principle, pragmatic studies can be
undertaken to evaluate the advantages of improving inhaler
technique as an alternative to increasing the dose of
existing therapies; however, payers are likely to want to
see evidence that improving inhaler technique leads to
measureable health outcomes and resource saving benefits
in a real-life setting.
Reasons for inhaler errors
Multiple factors impact on inhaler use. These can be
grouped into several broad categories, which relate to the
device itself, the patient (consumer) or the health care
professional.
The device
There are many different types of inhaler devices available
to patients and they can differ in terms of:
 The way in which the inhaler dispenses the medication;
whether it is passively or actively generated (i.e. the
aerosol-generating properties which can be propellant,
mechanical, or compressed air)
 The type of formulation (e.g. solution, dry powder etc)
 Whether the inhaler contains medication in a single- or
multi-dose, is disposable or refillable, or contains
a reservoir
 Dose preparation for DPIs.
Each of the different drug delivery systems demands
a certain level of physical skill, manipulation, dexterity,
hand strength, lung capacity and/or hand-lung co-ordina-
tion in order to ensure optimal/correct inhaler use.22e26
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physical difficulties when using an inhaler device.27
Therefore, there may be an increased risk of inhaler
errors if due consideration is not given to the patients’
individual practical abilities when prescribed inhaler
devices. The following considerations are suggested:
 Check natural inhaler technique e if the patient tends
to breathe in slowly use an MDI or fast and hard use
a DPI10
 Keep device consistent e don’t mix MDI and DPI
inhalers28
 Check for usage errors e if the patient displays errors of
actuation and inhalation use a breath actuated MDI
(BAI) or a small particle formulation
 Use training aids for encouraging slow inhalation with
MDI devices.
The patient/consumer
In addition to physical capabilities, several other patient-
related factors may impact on inhaler use including their
health beliefs/beliefs about medications, adherence and
patient device preference. While understanding the
patient’s psychosocial status and the way in which it
impacts on health behavior is complex, some key criteria
need to be considered in terms of inhaler use.
In order to optimize disease management, patients are
required to demonstrate correct inhaler technique, both at
the outset of treatment and as they continue to use their
inhaler over time.21 However, studies indicate that
between 40 and 60% of people with asthma are non-
adherent to their medication.29e31 Patients’ beliefs about
their condition and medications impact on their level of
adherence to regular medication.23,32e40 Patients who
believe using their inhaler is an important part of their
asthma management demonstrate higher levels of correct
inhaler use.32 Another important factor to consider is
patient preference for inhalers. This can be classified in
terms of operational use (e.g. ease of learning to use,
holding and operating, cleaning etc), convenience (e.g.
size, color, shape, durability, weight, etc) and oral sensa-
tion (e.g. taste and irritation). Evidence indicates that
patients do express preference for particular inhaler
devices and that this is associated with increased ease of
teaching the patient how to use the inhaler as well as
increased likelihood of correct use.41,42
The healthcare professional
The role of healthcare professionals in inhaler use is crit-
ical, both in achieving initial correct inhaler technique and
also in maintaining this correct inhaler use over time.
Inhaler technique training delivered to patients by
healthcare professionals is important in terms of the
nature, frequency and skill level demonstrated. Only
15e69% of healthcare professionals (across all disciplines)
can demonstrate correct inhaler use,43e47 a low proportion
of patients receive inhaler use education48 and an even
smaller proportion of patients have their inhaler technique
reviewed over time.48 Consequently, approximately half ofpatients who initially learn how to use their inhalers prop-
erly, do not maintain this correct technique over time.49 As
is becoming normal for spirometry testing, a system of
validation of training ability and inhalation assessment is
proposed, for healthcare professionals who prescribe
inhalers.
Another critical concept is the nature of the education
delivered. The most effective patient training technique in
correct inhaler use has been found to be verbal instruction
combined with physical demonstration.38,48,50 Repeating
this education over time increases the proportion of
patients returning to follow-up visits who maintain the
correct technique.21,49
Cultural barriers and inhaler use in asthma
Barriers including religious and cultural beliefs may impact
on the use of inhalers and reduce the impact of educational
interventions.51 In some populations, the use of an inhaler
is seen as improper or impolite and oral drugs may be
favored. Moreover, healthcare professionals need to be
aware that some CFC-free inhalers contain alcohol, since
certain populations may have religious and/or cultural
concerns regarding the use of such preparations.52
Improvement of inhaler technique from
a technology perspective
There are two major compliance issues for patients using
medication: intentional and unintentional non-compliance.
Unintentional non-compliance occurs when a patient
makes inadvertent mistakes using the device. This issue can
be addressed with technology by making devices more ‘self
explanatory’. The number of possible errors should be
investigated by conducting handling studies. The more
complex an instruction and the more handling steps needed
to start the inhalation process, the greater the chance of an
error occurring. For example, if the activation of a device is
needed as a separate step, this step could be combined
with another, resulting in a simpler instruction such as, ‘on
removing the cap, the device is activated’.
A patient’s breathing capacity is a key factor as it
determines the amount of drug reaching the lungs.10
Technical developments can help patients to breathe in
correctly by providing instructions on potential errors.
Intentional non-compliance exists when the patient
decides to refrain from taking themedication, to only take it
from time to time or to knowingly use the wrong inhalation
technique. This issue is more difficult to address with device
developments. As an important first step, the reasons for the
patient’s behavior should be determined. In some cases,
electronic compliance monitoring and motivation by (auto-
mated) reminders might be a helpful solution. The patient
should understand the benefits of using the medication on
a regular basis and appreciate the importance of each
handling step.Withmodern information technology it should
be possible to give instructions and to explain likely errors
and mishandling.
In cases of severe or uncontrolled disease,1 patients
should be offered a self-monitoring system and/or a tool
which enables a professional instructor (nurse, MD,
Table 1 Critical inhaler handling errors associated with specific inhaler devices. Critical errors are defined as when a patient
performs an error, displays imperfect technique or lacks knowledge on usage or maintenance of the inhaler device that is likely
to significantly impair the delivery of adequate medication on all occasions.
Device Critical error
Metered dose inhalers (MDIs)
without a spacer
Failure to remove the cap
Not holding the inhaler upright
Actuation not corresponding to inhalation; actuation before inhalation
Actuation not corresponding to inhalation; actuation is too late (Puff 1)
Failure to actuate
Failure to inhale
Inhale too fast
Inhalation through the nose
When asked e patient does not know how to tell that their device is empty
Metered dose inhalers (MDIs)
with a spacer
Failure to ensure a tight seal when mouthpiece is inserted into spacer. There
should be a click heard with the Volumatic and with the AeroChamber device.
It should be inserted with tight seal and the inhaler should be vertical at 90
Failure to hold spacer with inhaler upright
Failure to actuate just one dose into the spacer (either no dose actuated or
actuates more than one dose)
Spacer mouthpiece is inserted correctly but failure to seal lips
Failure to inhale through mouthpiece within 2 s of discharging one dose
Failure to actuate a dose into the spacer
Failure to inhale
Inhalation through the nose
Failure to hold breath (or to hold for <3 s)
When using two doses, starting to inhale through mouthpiece within 2 s of
discharging the first dose
Coughing during the inhalation
If prescribed Fostair, failure to know that they should use their inhaler within
20 weeks/5 months after receiving it from the pharmacy
Spacer has faulty parts, valves, or cracks in the plastic
Having washed the device in soapy/detergent water
Failure to air dry the device
Failure to remove the cap
Dry powdered inhalers (DPI):
Accuhaler
Failure to slide cover as far as possible
Failure to slide lever fully to open mouthpiece
Holding in a downward position after dose preparation (before inhalation)
Shaking after dose preparation
Blowing into the device before inhalation
Failure to put in mouth and seal lips around mouthpiece
Inhalation is not forceful from the start
Failure to inhale through mouthpiece
Inhalation through the nose
Failure of the patient to know when the device is empty
Dry powdered inhalers (DPI):
Turbohaler
Failure to remove cap
Shaking during preparation
Device not held upright (mouthpiece skywards) when the base is twisted
during dose preparation (within 45)
Dose not prepared correctly e twisting the base until it clicks
Dose not prepared correctly e turning it back to the original position
Device not held upright (mouthpiece skywards) after the base is twisted
until inhalation (within 45)
Shaking after dose preparation
Failure to put in mouth and seal lips around mouthpiece
Inhalation is not as fast as the patient can achieve (defined as a very fast suck)
Inhalation is not forceful from the start
Failure to inhale through mouthpiece
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Inhalation through the nose
Failure to slide cover as far as possible and then lever to open mouthpiece
Failure to breathe out slowly to empty the lungs
Breathing out into the device before inhalation
Failure to tilt head such that the chin is slightly upwards
Inhalation is not as long as the patient can achieve
Failure to hold breath (or to hold for <3 s)
Failure to replace cap after second inhalation
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systems which monitor and give feedback to patients with
asthma has been shown.53 In the future electronic moni-
toring and feedback systems, used in combination with
inhalation devices, may make this much easier to achieve.
However, it remains undetermined whether patients and
healthcare professionals are in favor of routinely using such
monitoring. Compliance monitoring has been attempted in
the clinical trial setting, but even in this situation it is of
limited value. Furthermore, compliance monitoring does
not confirm that the prescribed treatment is regularly
reaching the patient’s airways. The identification of
biomarkers which could determine the dose of medication
received by the target tissues is a potential future research
objective.
Another aspect which should be considered is the age of
the patient. Children will need different devices to those
used with adolescents and adults. In addition, elderly
patients will also have different device requirements and
may need special features incorporated. Younger patients
typically prefer smaller, more technical delivery systems.
In contrast, elderly or disabled patients might benefit from
larger devices which can be handled easily and which have
clearer displays and larger actuators.
To summarize, technical solutions exist for both types of
non-compliance. The age of the patient using the device
should always be considered.
Educational interventions to reduce inhaler
technique errors
Few studies have rigorously examined interventions to
improve and maintain skill in inhaler use and reduce error.
Inadequate inhaler technique decreases the effective
delivery of drugs, thus interventions which reduce inhaler
error may improve patient outcomes.17,27,54 Although
multiple studies suggest that new “improved” inhaler
devices reduce errors and improve outcomes, a review of
controlled trials demonstrated that a broad range of inhaler
devices are equally effective in delivering therapy when
patients use them appropriately.55
Improving healthcare professional inhaler
knowledge and skills
While virtually all comprehensive patient education
programs include some level of education about the
correct use of inhalers, most patients do not participate in
such formal programs and instead rely on instruction
received from healthcare professionals in the clinic.However, these healthcare professionals typically lack the
appropriate knowledge and skills in using different inhaler
devices.56 For this reason, studies have examined educa-
tional interventions designed to “train the trainer” and
improve healthcare professional inhaler competence. It
has been demonstrated that a single education session
improves medical residents’ inhaler knowledge and skills.57
Another study demonstrated that pharmacists who partic-
ipated in a single-session education workshop showed
significantly better knowledge and skills than a control
group, and that this knowledge was retained at a high
level.58 Internet-based, interactive, multimedia tutorials
represent a promising, new low-cost mechanism for
educating healthcare professionals. It has been shown that
a small-group lecture format with web-based tutorial
significantly improved pharmacy students’ knowledge of
MDI technique.59 Similar effectiveness of a web-based
inhaler tutorial designed for healthcare professionals has
also been reported.60
Improving patient inhaler knowledge and skills
Focused educational interventions designed to improve
inhaler skills of adults and children with MDIs, pMDIs and
DPIs can result in significant reduction in patient inhaler
error.21,49,61e66 Written and verbal instructions alone
improved patient technique, but the addition of a physical
demonstration delivered by a pharmacist resulted in
markedly better retention of inhaler skills.49 Another study
showed that a simple 2.5 min inhaler education interven-
tion delivered by trained community pharmacists not only
significantly improved patient inhaler technique but also
resulted in improved asthma outcomes.21 Other educa-
tional strategies for improving the efficacy of inhaler
technique include the use of multimedia computer
presentations,64,65 use of a training aid (2Tone Trainer),1
and telepharmacy counseling combined with an interac-
tive video.66Specific challenges for pediatric inhaler use
Patients of all ages can demonstrate problems when using
their inhalers. Each inhalation method and age group
presents specific problems but most children can be
successfully trained to effectively use their inhalation
device, no matter which method it utilizes.5 The choice of
inhaler device for preschool children is limited to either
nebulizers or a pMDI plus a spacer. In school children all
inhalation methods can be used and the choice depends on
the child’s ability and preference.67
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In pre-school children the choice between pMDI and spacer
or nebulizer is an individual choice. It is important that
a facemask is used, and that this fits tightly and the child is
not crying whilst using the inhaler.67 Nasal breathing
provides sufficient lung deposition in these patients. The
percentage of lung deposition is correlated to age and
weight68,69 and the inhaled dose therefore increases with
age or weight.70 Even the low deposition values reported in
babies68 should be sufficient to manage their disease.School children and adolescents
Lung deposition
In older children inhalation through the mouth provides
better lung deposition than nasal breathing.68 As soon as
the child can cope they should be switched from a mask to
a mouthpiece, and use a single deep inhalation instead of
tidal breathing.67 When using tidal breathing in 2e7 year
olds, 2 and 3 breaths with a small and a large spacer are
sufficient for adequate dosing.71 For the concomitant
treatment of allergic rhinitis and asthma, exclusive nasal
inhalation through a facemask (mouth closed) attached to
a large volume valved spacer may be as effective as the
dual (intranasal plus inhaled corticosteroid) conventional
treatment.72
Spacers
Spacers are useful in children and other patients that have
problems using a pMDI or DPI. A variety of spacers, ranging
from small to large volume, are available.67 Conflicting
reports claim70 or deny73 that differences exist between
spacers. Plastic spacers with antistatic properties appear to
provide better lung deposition than those without,67 even
when compared with metal ones.74 Each spacer has its own
particular recommended washing and use procedures and
so it is important to follow the instructions in the Patient
Information Leaflet.67 Static delays in inhalation and
multiple actuations decrease the dose emitted and use is
restricted due their bulk.67 In developing countries home-
made non-valved spacers provide equivalent efficacy to
the commercially available spacers.75
DPI and pMDI use
Changing children to portable inhalers is age-dependent and
DPIs can be introduced successfully at an earlier age than
a BAI or a pMDI.5 However, children may have problems
achieving the DPI and pMDI recommended techniques.5 It is
important, therefore, that they are reviewed regularly by
those who have received inhalation technique training and
can themselves competently use these devices.
A DPI should be used with an inhalation that is as
forceful as the patient can achieve and this should be
continued for as long as possible.67 The inhalation should be
forceful from the start rather than build gradually. These
inhalation maneuvers with a DPI are necessary to provide
sufficient turbulent energy to de-aggregate the metered
dose during an inhalation so that the emitted dose has the
potential for lung deposition.76 A pMDI should be used with
a slow inhalation, continued for as long as possible, and theactuation of the dose should be made when the subject
starts to inhale.67
Inhalation flow with DPI
Using an inhalation that is as fast as possible from the
beginning and continued for as long as possible is impor-
tant.67 De-aggregation of the formulation in the metered
dose of a DPI occurs as a result of the turbulent energy
generated by the interaction of the patient’s inhalation flow
with the DPI’s resistance.76 The peak inhalation flow of
children through a DPI increases with age77 and decreases
during acute exacerbations.78e80 The peak inhalation flow
achieved through each type of DPI is related to its internal
resistance and the patient.76 This leads to children achieving
lower flows when the resistance of the DPI is higher.79e81
Lung deposition69 and clinical response in children77 is
probably related to an insufficient turbulent energy leading
to inefficient de-aggregation. For a medium/high resistance
DPI, this de-aggregation is reduced when the inhalation flow
is less than 30 l/min.82 However if the DPI’s resistance is
higher, then usually the minimum threshold turbulent
energy will occur at a lower flow to provide an effective
clinical response.83
Coordination with pMDI
Coordination between dose actuation and the start of an
inhalation, as well as using a slow inhalation, are important
to ensure good penetration into the lungs.67 Inhalation
technique errors are more common in children using
a pMDI.84e86 Fast inhalation is a common error86 but
training children to inhale slowly may be difficult.5
Although BA-pMDIs would help and should be easier to
train children how to use,5 the range of drugs is limited and
the licensing of BA-pMDI corticosteroids does not generally
extend to children. Extra-fine particles may be less
dependent on an optimal inhalation technique67 and
provide good, lung deposition in children.87,88 However, the
range of these products is limited and is mainly restricted
to off-label prescribing in children.
Training in inhaler technique
In all age groups training in inhaler technique is useful for
each type of inhaler84,85,89,90 and should be repeated at
regular intervals.84,85 A lower inhaled corticosteroid dose
and improved asthma control occurs in children when the
inhalation technique improves.91The need for policy change
There is clearly a need for policy makers to grasp the
importance of improving inhaler technique through the
strategies discussed in this paper. By instituting programs to
address inhaler technique assessment and training in all
health care settings, substantial health gain could be ach-
ieved. Health care costs for asthma would be decreased
and future increases in expenditure reduced. The recent
call for action published in the European Respiratory
Society Journal10 which emphasized the importance of
correct inhaler choice, proper training and ongoing
education to maintain technique merits support at the
policy level to achieve its desired outcomes.
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steps
Asthma control and COPD outcomes are clearly sub-optimal
and inferior in clinical practice to those obtained in clinical
trials. A major contributing factor appears to be poor
inhaler technique and all of its consequences. Extensive
studies are required on the impact of the inhalation tech-
nique in achieving optimal asthma control.92 These studies
could identify the most effective training methods, tools or
inhalers.
At a time of increasing prevalence of obstructive lung
disease against a background of restricted health care
spending, making the most effective use of inhaler devices
has now become a priority for all involved, whether they
are health care providers, governmental bodies,
researchers, health care professional groupings or patient
organizations. Key aspects of this issue are shown in Table 2
which summarizes the research, policy, educational and
pharmacoeconomic needs. We are clearly at the point
where the problem of inhaler misuse can no longer be
ignored but should be fully embraced by all parties involved
in providing care for patients with obstructive lung disease.Acknowledgments
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